Compare RFL & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RFL | LUNG |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 72.2M |
| IPO Year | 2017 | 2020 |
| Metric | RFL | LUNG |
|---|---|---|
| Price | $1.22 | $1.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 68.9K | ★ 715.9K |
| Earning Date | 03-16-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.28 | 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | $917,000.00 | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.96 | 8.01 |
| 52 Week Low | $1.12 | $1.13 |
| 52 Week High | $3.19 | $7.01 |
| Indicator | RFL | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 42.68 |
| Support Level | $1.15 | N/A |
| Resistance Level | $1.59 | $1.93 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 7.41 | 32.87 |
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.